Astragaloside IV ameliorates diabetic kidney disease by modulating the PHD2/HIF-1α axis and inhibiting podocyte ferroptosis
Biochemical Pharmacology · 2026
DOI: 10.1016/j.bcp.2026.118285 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical Pharmacology, 2026. Verfasst von YaXiong Guo und 7 weiteren Autor:innen. Beteiligte Einrichtung: No. 1 Clinical Medical School, Shanxi Medical University, Taiyuan, Shanxi Province 030000, China; Surgical Unit 1, Shanxi Combined Traditional Chines…. Hauptthemen laut MEDLINE: Triterpenes, Podocytes, Saponins, Diabetic Nephropathies. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Diabetic kidney disease (DKD) lacks therapies that directly target podocyte injury, and the upstream regulation of HIF-1α-driven ferroptosis in podocytes remains unclear. This study investigated whether astragaloside IV (AS-IV) protects against DKD by regulating the PHD2/HIF-1α axis. A DKD mouse model was induced by a high-fat/high-sugar diet plus streptozotocin, followed by AS-IV intervention (100 mg/kg/day for 12 weeks). In vitro, podocytes were exposed to high glucose (30 mM) with AS-IV (40 μmol/L), along with the HIF-1α inhibitor LW6 or activator DMOG. Network pharmacology and molecular docking identified HIF-1α signaling as a core pathway, with stable binding of AS-IV to PHD2 and HIF-1α. AS-IV improved renal function and pathology in DKD mice without affecting blood glucose. In vivo and in vitro, AS-IV activated PHD2, promoted HIF-1α ubiquitination and degradation, and subsequently inhibited podocyte ferroptosis, as shown by reduced iron accumulation and lipid peroxidation, and upregulated GPX4 and SLC7A11. Additionally, AS-IV suppressed pyroptosis and inflammation (reduced NLRP3, GSDMD-NT, IL-1β, IL-18) and modulated apoptosis (increased Bcl2). In conclusion, the renoprotective effect of AS-IV is mediated through the PHD2/HIF-1α axis, reducing HIF-1α accumulation and thereby inhibiting podocyte ferroptosis, pyroptosis, inflammation, and fibrosis in DKD. These findings provide a novel mechanistic foundation for AS-IV as a prospective therapeutic agent for DKD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- No. 1 Clinical Medical School, Shanxi Medical University, Taiyuan, Shanxi Province 030000, China; Surgical Unit 1, Shanxi Combined Traditional Chinese and Western Medicine Hospital, Taiyuan, Shanxi Province 030072, Chin…
- No. 1 Clinical Medical School, Shanxi Medical University, Taiyuan, Shanxi Province 030000, China.
- Shanxi Provincial Key Laboratory of Otorhinolaryngology Head and Neck Cancer, The First Hospital of Shanxi Medical University, Taiyuan 030001, China.
- Department of Nephrology, First Hospital of Shanxi Medical University, No. 85, Jiefang South Road, Taiyuan 030001, China.
- Department of Nephrology, Shanxi Provincial People's Hospital (The Fifth Clinical Medical College of Shanxi Medical University), Taiyuan, Shanxi 030012, China; Shanxi Provincial Key Laboratory of Kidney Disease, Taiyuan…
- Department of Urology, First Hospital of Shanxi Medical University, No. 85, Jiefang South Road, Taiyuan 030001, China. Electronic address: dr2017003@d.sxmu.edu.cn.
Zitieren
APA
Guo, Y., Wang, H., Yan, P., Zhang, Y., Hu, Y., Zhao, Z., Liu, C., & Liu, Y. (2026). Astragaloside IV ameliorates diabetic kidney disease by modulating the PHD2/HIF-1α axis and inhibiting podocyte ferroptosis. Biochemical Pharmacology. https://doi.org/10.1016/j.bcp.2026.118285
Vancouver
Guo Y, Wang H, Yan P, Zhang Y, Hu Y, Zhao Z, et al. Astragaloside IV ameliorates diabetic kidney disease by modulating the PHD2/HIF-1α axis and inhibiting podocyte ferroptosis. Biochemical Pharmacology. 2026. doi:10.1016/j.bcp.2026.118285
BibTeX
@article{Guo2026,
author = {Guo, YaXiong and Wang, HuiFang and Yan, PengYu and Zhang, YuLiang and Hu, YaLing and Zhao, ZhiBo and Liu, Chun and Liu, YuXiang},
title = {Astragaloside IV ameliorates diabetic kidney disease by modulating the PHD2/HIF-1α axis and inhibiting podocyte ferroptosis},
journal = {Biochemical Pharmacology},
year = {2026},
doi = {10.1016/j.bcp.2026.118285}
}
EUVIMED